Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season

Puig-Barberà, Joan; Guglieri-López, Beatriz; Tortajada‐Girbés, Miguel; López‐Labrador, F. Xavier; Carballido‐Fernández, Mario; Mollar-Maseres, Joan; Schwarz‐Chavarri, Germán; Baselga-Moreno, Víctor; Mira‐Iglesias, Ainara; Díez‐Domingo, Javier

doi:10.1016/j.vaccine.2017.10.100

Cited by 18 publications

(23 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the 2015‐2016 season, subclades 6B.1 and 6B.2 appeared as new clusters in clade 6B. In Turkey, all studied influenza A(H1N1)pdm09 isolates of this season belonged only to 6B.1 as detected in studies by Komissarov et al, Korsun et al, Clark et al, Puig‐Barberà et al, Mohebbi et al Cocirculation of 6B.1 and 6B.2 isolates was also observed in some other studies …”

Section: Discussionsupporting

confidence: 64%

“…31 Accordingly, S162N was suggested as a specific mutation due to a potential gain of new glycosylation site that may shield the Sa epitope for escaping the pre-existing immunity. [20][21][22]26 Further to these common mutations, a rare mutation detected in our study, T72A, was also residing in Cb. and 2015-2016 seasons.…”

Section: Sequence Analysis Of Nas For the Presence Of H275y Mutationsupporting

confidence: 57%

“…Glycosylation of HA has been recognized as another factor affecting antigenicity and playing important role in the evolution of influenza A(H1N1)pdm09 viruses since variations of the carbohydrate site chains on HA have been shown to alter the antibody‐mediated neutralization of virus . Accordingly, S162N was suggested as a specific mutation due to a potential gain of new glycosylation site that may shield the Sa epitope for escaping the pre‐existing immunity . Further to these common mutations, a rare mutation detected in our study, T72A, was also residing in Cb.…”

Section: Discussionmentioning

confidence: 58%

“…The common HA mutations detected in Turkish isolates of the 2015‐2016 season have previously been identified by other groups, and the accessibility of residues associated with antigenic sites and their possible impact in the antigenicity of the protein has already been discussed in detail . Despite carrying a higher number of HA mutations compared to the progenitor virus, the new subclades 6B.1 and 6B.2 of the 2015‐2016 season were closely related to the vaccine virus A/California/7/2009 and found to be antigenically indistinguishable by postinfection ferret antisera.…”

Section: Discussionmentioning

confidence: 72%

“…Since emergence in 2009, the genetic makeup of influenza A(H1N1) pdm09 virus has been changing for both to adapt to new hosts and survive in different geographic and seasonal conditions. 18 19 Korsun et al, 20 Clark et al, 21 Puig-Barberà et al, 22 Mohebbi et al 23 Cocirculation of 6B.1 and 6B.2 isolates was also observed in some other studies. [24][25][26][27][28] In the 2009-2010 and 2010-2011 seasons, the HA nucleotide sequence similarity rates between Turkish isolates and the A/ California/07/2009 virus were >98.9% and >98.7%, respectively, 11,12 but the similarity ranging 96.6% to 97.2% we observed in the 2015-2016 season was pointing out a rising divergence from the progenitor virus compared to the previous seasons.…”

Section: Sequence Analysis Of Nas For the Presence Of H275y Mutationmentioning

confidence: 74%

See 4 more Smart Citations

Molecular characterization of the influenza A(H1N1)pdm09 isolates collected in the 2015‐2016 season and comparison of HA mutations detected in Turkey since 2009

Güldemir

Coşkun-Ari

Altaş

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Influenza A(H1N1)pdm09 pandemic virus causing the 2009 global outbreak moved into the post‐pandemic period, but its variants continued to be the prevailing subtype in the 2015‐2016 influenza season in Europe and Asia. To determine the molecular characteristics of influenza A(H1N1)pdm09 isolates circulating during the 2015‐2016 season in Turkey, we identified mutations in the hemagglutinin (HA) genes and investigated the presence of H275Y alteration in the neuraminidase genes in the randomly selected isolates. The comparison of the HA nucleotide sequences revealed a very high homology (>99.5%) among the studied influenza A(H1N1)pdm09 isolates, while a relatively low homology (96.6%‐97.2%), was observed between Turkish isolates and the A/California/07/2009 vaccine virus. Overall 14 common mutations were detected in HA sequences of all 2015‐2016 influenza A(H1N1)pdm09 isolates with respect to the A/California/07/2009 virus, four of which located in three different antigenic sites. Eleven rare mutations in 12 HA sequences were also detected. Phylogenetic analysis revealed that all characterized influenza A(H1N1)pdm09 isolates formed a single genetic cluster, belonging to the genetic subclade 6B.1, defined by HA amino acid substitutions S84N, S162N, and I216T. Furthermore, all isolates showed an oseltamivir‐sensitive genotype, suggesting that Tamiflu (Oseltamivir) could still be the drug of choice in Turkey.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Sequence Analysis Of Nas For the Presence Of H275y Mutationsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 72%

Section: Sequence Analysis Of Nas For the Presence Of H275y Mutationmentioning

confidence: 74%

See 3 more Smart Citations

Molecular characterization of the influenza A(H1N1)pdm09 isolates collected in the 2015‐2016 season and comparison of HA mutations detected in Turkey since 2009

Güldemir

Coşkun-Ari

Altaş

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015–2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation

et al. 2019

View full text Add to dashboard Cite

Background We estimated influenza vaccine effectiveness (VE) in 2015–2016 season against medically attended, laboratory-confirmed influenza, when quadrivalent inactivated vaccine (IIV4) was first introduced in Japan, using test-negative case-control design. Influenza A(H1N1)pdm09 cocirculated with B/Yamagata and B/Victoria during the study period in Japan. Method We based our case definition on two laboratory tests, real-time reverse transcription polymerase chain reaction (RT PCR), and virus isolation and compared VEs based on these tests. In addition, VE was evaluated by rapid diagnostic test (RDT). Nasopharyngeal swabs were collected from outpatients who visited clinics with influenza-like illness (ILIs) in Hokkaido, Niigata, Gunma and Nagasaki prefectures. Results Among 713 children and adults enrolled in this study, 578 were influenza positive by RT PCR including, 392 influenza A and 186 influenza B, while 135 were tested negative controls. The adjusted VE by RT PCR for all ages against any influenza was low protection of 36.0% (95% confidence interval [CI], 3.1% to 58.6%), for influenza A was 30.0% (95% CI: −10.0% to 55.5%), and influenza B was moderate 50.2% (95% CI: 13.3% to 71.4%). Adjusted VE for virus isolation for A(H1N1)pdm09 was 37.1% (95% CI: 1.7% to 59.7%), Yamagata lineage 51.3% (95% CI: 6.4% to 74.7%) and Victoria lineage 21.3% (95% CI: −50.0% to 58.9%). VE was highest and protective in 0–5 years old group against any influenza and influenza A and B/Yamagata, but the protective effect was not observed for other age groups and B/Victoria. RDT demonstrated concordant results with RT PCR and virus isolation. Sequencing of hemagglutinin gene showed that all A(H1N1)pdm09 belong to clade 6B including 31 strains (88.6%), which belong to clade 6B.1 possessing S162N mutations that may alter antigenicity and affect VE for A(H1N1)pdm09. Conclusions IIV4 influenza vaccine during 2015–2016 was effective against A(H1N1)pdm09 and the two lineages of type B. Younger children was more protected than older children and adults by vaccination.

show abstract

Evaluation of A(H1N1)pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells

et al. 2019

View full text Add to dashboard Cite

The recent reduction of live attenuated influenza vaccine (LAIV) effectiveness in multivalent formulations was particularly associated with the A(H1N1)pdm09 component. In the 2017 the WHO vaccine composition committee changed its recommendations for the A(H1N1)pdm09 component to include an A/Michigan/45/2015-like virus. We evaluated effectiveness and quality of newly developed and previous A(H1N1)pdm09 LAIV reassortants through assessment of their thermal and pH stability, receptor binding specificity and replication fitness in primary human airway epithelial cells of nasal origin (hAECN). Our analysis showed that LAIV expressed hemagglutinin (HA) and neuraminidase (NA) from an A/Michigan/45/2015-like strain A/New York/61/2015 (A/New York/61/2015-CDC-LV16A, NY-LV16A), exhibit higher thermal and pH stability compared to the previous vaccine candidates expressing HA and NA from A/California/07/2009 and A/Bolivia/559/2013 (A17/Cal09 and A17/Bol13). Reassortants A/South Africa/3626/2013-CDC-LV14A (SA-LV14A) and NY-LV16A showed preferential binding to α2,6 sialic acid (SA) receptors and replicated at higher titers and more extensively in hAECN compared to A17/Cal09 and A17/Bol13, which had an α2,3 SA receptor binding preference. Our data analysis supports selection of A/New York/61/2015-CDC-LV16A for LAIV formulation and the introduction of new assays for LAIV characterization.

show abstract

Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season

Cited by 18 publications

References 37 publications

Molecular characterization of the influenza A(H1N1)pdm09 isolates collected in the 2015‐2016 season and comparison of HA mutations detected in Turkey since 2009

Molecular characterization of the influenza A(H1N1)pdm09 isolates collected in the 2015‐2016 season and comparison of HA mutations detected in Turkey since 2009

Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015–2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation

Evaluation of A(H1N1)pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells

Contact Info

Product

Resources

About